<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923361</url>
  </required_header>
  <id_info>
    <org_study_id>00116093B</org_study_id>
    <nct_id>NCT03923361</nct_id>
  </id_info>
  <brief_title>Neural and Antidepressant Effects of Propofol (Phase 2)</brief_title>
  <official_title>Neural and Antidepressant Effects of Propofol (Phase 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moderate-intensity propofol treatments will be administered to participants who are
      non-responders at the end of Phase 1.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change in study design based on phase 1 data collection; patient burden was not feasible
  </why_stopped>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>3 weeks after baseline</time_frame>
    <description>24-item Hamilton Depression Rating Scale, total score Higher values represent more severe depressive symptoms Maximum score, 76; minimum score, 0 Remission defined as total score &lt; 10 Response defined as decrease of total score from baseline &gt; 50%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprivan</intervention_name>
    <description>Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-55

          -  Diagnosis of major depressive disorder or bipolar disorder

          -  Current moderate-to-severe depressive episode

          -  Episode duration more than 2 months and less than 5 years

          -  Failure of at least 2 adequate antidepressant medication trials within the past 2
             years

          -  Body mass index &lt; 40

          -  16-item Quick Inventory of Depressive Symptomatology, self-rated &gt; 10

        Exclusion Criteria:

          -  Contraindication to propofol or midazolam

          -  Daily use of benzodiazepine, opioid, ACE inhibitor, or ARB medication

          -  Symptomatic coronary artery disease or heart failure

          -  Poorly controlled hypertension or diabetes

          -  Abnormal kidney or liver function

          -  Pregnant or breast feeding

          -  Traumatic brain injury or significant neurologic signs (past year)

          -  Substance use disorder (past year)

          -  Obsessive compulsive disorder (current)

          -  Post-traumatic stress disorder (current)

          -  Schizophrenia-spectrum disorder (lifetime)

          -  Neurocognitive disorder (current)

          -  Personality disorder as a current focus of treatment

          -  ECT within the past 3 months

          -  Inappropriate for ECT, or poor response to ECT within the past 5 years

          -  Incompetent to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univeristy Neuropsychiatric Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Brian Mickey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

